Transcriptional profiling of whole blood: A rich source of immune biomarkers in cancer

Y. Saenger; E. de Moll; Y. Fu

doi:10.4161/21624011.2014.944056

Transcriptional profiling of whole blood: A rich source of immune biomarkers in cancer

Y. Saenger
, E. de Moll
, Y. Fu

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Immunotherapy is at the forefront of cancer treatment, and biomarkers are urgently needed to predict patient response to therapy. Recently, we discovered a 4-gene peripheral blood mRNA signature for prolonged survival in patients treated with tremelimumab. Peripheral blood mRNA is a readily accessible and under-utilized source of clinically relevant biomarkers.

Original language	English
Article number	e944056
Journal	OncoImmunology
Volume	3
Issue number	7
DOIs	https://doi.org/10.4161/21624011.2014.944056
State	Published - 2014

Keywords

Biomarker
Immunotherapy
Peripheral blood
Tremelimumab
mRNA

Access to Document

10.4161/21624011.2014.944056

Cite this

@article{b2e4d047fc27493ebf8ebd038b684d1f,

title = "Transcriptional profiling of whole blood: A rich source of immune biomarkers in cancer",

abstract = "Immunotherapy is at the forefront of cancer treatment, and biomarkers are urgently needed to predict patient response to therapy. Recently, we discovered a 4-gene peripheral blood mRNA signature for prolonged survival in patients treated with tremelimumab. Peripheral blood mRNA is a readily accessible and under-utilized source of clinically relevant biomarkers.",

keywords = "Biomarker, Immunotherapy, Peripheral blood, Tremelimumab, mRNA",

author = "Y. Saenger and \{de Moll\}, E. and Y. Fu",

note = "Publisher Copyright: {\textcopyright} 2014 Taylor \& Francis Group, LLC.",

year = "2014",

doi = "10.4161/21624011.2014.944056",

language = "English",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Transcriptional profiling of whole blood

T2 - A rich source of immune biomarkers in cancer

AU - Saenger, Y.

AU - de Moll, E.

AU - Fu, Y.

PY - 2014

Y1 - 2014

N2 - Immunotherapy is at the forefront of cancer treatment, and biomarkers are urgently needed to predict patient response to therapy. Recently, we discovered a 4-gene peripheral blood mRNA signature for prolonged survival in patients treated with tremelimumab. Peripheral blood mRNA is a readily accessible and under-utilized source of clinically relevant biomarkers.

AB - Immunotherapy is at the forefront of cancer treatment, and biomarkers are urgently needed to predict patient response to therapy. Recently, we discovered a 4-gene peripheral blood mRNA signature for prolonged survival in patients treated with tremelimumab. Peripheral blood mRNA is a readily accessible and under-utilized source of clinically relevant biomarkers.

KW - Biomarker

KW - Immunotherapy

KW - Peripheral blood

KW - Tremelimumab

KW - mRNA

UR - https://www.scopus.com/pages/publications/84911368946

U2 - 10.4161/21624011.2014.944056

DO - 10.4161/21624011.2014.944056

M3 - Article

AN - SCOPUS:84911368946

SN - 2162-4011

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 7

M1 - e944056

ER -

Transcriptional profiling of whole blood: A rich source of immune biomarkers in cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this